Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

PENBullishIndustry Newsnews

High materiality9/10

FDA Clears DVT Indication for Penumbra Lightning CAVT, Expanding TAM

Oct 20, 2026, 1:31 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Regulatory clearance broadens PEN's TAM and validates CAVT's clinical value, likely prompting upside, albeit moderated by deal uncertainty with BSX.

AI summary

What happened, with direct paths to the underlying reporting

Penumbra announced FDA clearance for DVT treatment using Lightning CAVT, based on BOLT-DVT results. The trial showed rapid clot removal and favorable safety with 98% removal and 18-minute device times, suggesting CAVT could become a first-line DVT option and expand Penumbra's TAM. Key outcomes include low adverse events, durable patency, and quality-of-life improvements.

FDA clears DVT indication for Lightning CAVT; expands PEN's addressable market. Positive BOLT-DVT data underpins the decision.
BOLT-DVT: 98% thrombus removal; 18-minute median device time. 3.1% 48-hour MAE.
No device deaths; 30-day re-thrombosis 3.9%; patency 88.8-96.3% across vessels.
84.3% no PTS at 30 days; pain drops 5 to 0 post-procedure; QoL improves.
Penumbra cites pending Boston Scientific deal; regulatory clearance could influence deal dynamics.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

FDA Clears DVT Indication for Penumbra Lightning CAVT, Expanding TAM

Boston Scientific to Acquire Penumbra for $14.5 Billion in Medtech Deal

Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst

Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst